Does Blue Cross Blue Shield of Arizona Cover Saxenda?

What Saxenda Is and Why Coverage Is Complicated

Saxenda is a once-daily injectable GLP-1 receptor agonist that mimics the gut hormone glucagon-like peptide-1 to suppress appetite and slow gastric emptying. The FDA approved it on December 23, 2014, for adults with a BMI of 30 or higher, or a BMI of 27 or higher with at least one weight-related condition such as type 2 diabetes, hypertension, or dyslipidemia. The FDA prescribing information specifies that Saxenda must be used alongside a reduced-calorie diet and increased physical activity. [1]

Insurance coverage for weight-loss drugs has historically lagged behind cardiovascular and metabolic medications. The Affordable Care Act did not mandate obesity-drug coverage for most commercial plans, which means each insurer writes its own rules. BCBSAZ follows this pattern.

How BCBSAZ Structures Its Formulary

BCBSAZ uses a tiered drug formulary. Most commercial plans run four to five tiers. Saxenda typically lands on Tier 3 (preferred brand) or Tier 4 (non-preferred brand), both of which carry higher cost-sharing than generic alternatives. The National Institutes of Health explains GLP-1 receptor agonist pharmacology in detail, which provides useful background when writing a letter of medical necessity. [2]

Employer-sponsored self-funded plans administered by BCBSAZ set their own formularies. A plan that covers Saxenda for one employer group may exclude it entirely for another. Always request your plan's Summary of Benefits and Coverage (SBC) and the current formulary PDF before assuming coverage applies.

Why Prior Authorization Exists for Saxenda

Prior authorization (PA) exists because Saxenda costs the insurer substantially more than lifestyle interventions and because formulary placement decisions are made at a population level, not for individual patients. The Endocrine Society's 2015 clinical practice guideline on obesity pharmacotherapy states that "pharmacotherapy for obesity should be considered for patients who have not achieved their weight-loss goals through diet and physical activity alone." [3] Insurers use PA to verify that prescribers have documented this stepwise process.

BCBSAZ Prior Authorization Criteria for Saxenda

Most BCBSAZ commercial plans that list Saxenda require the prescriber to demonstrate all of the following before approving coverage.

Standard Medical Criteria

1. BMI threshold. BMI 30 or higher, or BMI 27 or higher with at least one qualifying comorbidity (type 2 diabetes, hypertension, hyperlipidemia, obstructive sleep apnea, or cardiovascular disease).
2. Prior weight-loss attempt. Documentation that the patient attempted a structured diet-and-exercise program for at least three to six months without adequate weight loss. Adequate is usually defined as less than 5% body weight reduction.
3. Absence of contraindications. Personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 are absolute contraindications per the FDA label. [1]
4. Prescriber type. Some plans limit coverage to prescriptions written by or in consultation with an endocrinologist, obesity medicine specialist, or primary care physician who has documented obesity as a diagnosis using ICD-10-CM code E66.

The American Association of Clinical Endocrinology 2016 obesity guidelines recommend individualized pharmacotherapy selection based on comorbidity profile, tolerability, and cost. [4] Submitting this guideline alongside your PA documentation strengthens the clinical argument.

Step Therapy Requirements

Several BCBSAZ plan designs impose step therapy, meaning the patient must try and fail one or more lower-cost obesity medications first. Phentermine/topiramate (Qsymia) or bupropion/naltrexone (Contrave) are the most common step-therapy agents because their average retail price is 60 to 80% lower than Saxenda. If your prescriber believes step therapy is medically inappropriate, they can request a step-therapy exception at the same time as the PA submission.

What to Include in the PA Packet

• Completed PA request form (available on the BCBSAZ provider portal)
• Most recent height, weight, and calculated BMI from chart notes
• Three-to-six-month diet-and-exercise trial documentation with dates
• ICD-10 codes for obesity and all relevant comorbidities
• A letter of medical necessity signed by the prescribing physician
• Relevant lab work (HbA1c, lipid panel, blood pressure readings)

The CDC National Center for Health Statistics data show that 41.9% of U.S. Adults had obesity in 2017 to 2020, which supports the argument that obesity is a chronic disease requiring pharmacotherapy, not a lifestyle choice. [5]

Clinical Evidence Behind Saxenda That Supports Your Appeal

When a PA is denied, the appeal must demonstrate that Saxenda is medically necessary for the specific patient. Citing the key trials by name and number is more persuasive than vague references to "clinical studies."

SCALE Obesity and Prediabetes Trial

The SCALE Obesity and Prediabetes trial (N=3,731) randomized adults with BMI 30 or higher (or BMI 27 or higher with dyslipidemia or hypertension) to liraglutide 3 mg or placebo for 56 weeks. Participants receiving liraglutide lost a mean of 8.4 kg (8.0% body weight) versus 2.8 kg (2.6%) with placebo (P<0.001). A full report appears in the New England Journal of Medicine. [6]

SCALE Diabetes Trial

The SCALE Diabetes trial (N=846) evaluated liraglutide 3 mg in adults with type 2 diabetes and BMI 27 or higher. Mean weight loss was 6.0% with liraglutide 3 mg versus 2.0% with placebo at 56 weeks (P<0.001). HbA1c dropped by 1.3 percentage points with the 3 mg dose. Published in JAMA Internal Medicine, this trial is available through PubMed. [7]

These numbers matter in an appeal letter because they demonstrate that Saxenda produces clinically meaningful weight reduction beyond placebo, not merely modest or marginal effects.

Cardiometabolic Context

The American Heart Association's scientific statement on obesity and cardiovascular disease notes that a 5 to 10% weight reduction improves blood pressure, fasting glucose, and triglyceride levels. See the AHA's position at the American Heart Association journal. [8] Connecting Saxenda's average weight loss to these downstream cardiometabolic benefits gives the insurer a cost-avoidance argument for approving the drug.

How to Appeal a Saxenda Denial from BCBSAZ

Denials are common. The framework below outlines the four-stage process most BCBSAZ members use to escalate from an initial denial to an independent external review.

Stage 1: Internal First-Level Appeal

File within 180 days of the denial notice (check your Explanation of Benefits for the exact deadline). Submit the denial letter, the original PA packet, the peer-reviewed citations from the SCALE trials, and the letter of medical necessity. BCBSAZ must respond to urgent appeals within 72 hours and standard appeals within 30 days under Arizona state law.

Stage 2: Internal Second-Level Appeal

If the first-level appeal fails, request a second-level review conducted by a different medical reviewer. At this stage, ask your prescriber to request a peer-to-peer call with the BCBSAZ medical director. Peer-to-peer calls result in approval approximately 30 to 50% of the time when the prescriber can speak directly to clinical specifics.

Stage 3: External Independent Review

Arizona law (A.R.S. § 20-3251 et seq.) gives members the right to an independent external review after exhausting internal appeals. The Arizona Department of Insurance and Financial Institutions oversees this process. External reviewers are independent physicians who must issue a decision within 45 days (standard) or 72 hours (expedited). Their decision is binding on BCBSAZ.

Stage 4: State Complaint

If the external reviewer upholds the denial and you believe the insurer violated Arizona coverage law, file a complaint with the Arizona Department of Insurance. This step is rare but available.

Saxenda Alternatives That BCBSAZ May Cover More Readily

If Saxenda remains excluded or too expensive after appeals, several alternatives may sit on a lower tier or carry fewer PA barriers on your specific plan.

Semaglutide (Wegovy, Ozempic)

Wegovy (semaglutide 2.4 mg weekly) received FDA approval for chronic weight management in June 2021. The STEP-1 trial (N=1,961) showed a mean weight loss of 14.9% at 68 weeks versus 2.4% with placebo (P<0.001). Full results are published in the New England Journal of Medicine. [9] Some BCBSAZ plan years list Wegovy on a preferred tier if semaglutide is the plan's preferred GLP-1 agent. Ozempic (semaglutide 0.5 to 2 mg weekly) is FDA-approved for type 2 diabetes and may carry different tier placement if the patient also has diabetes.

Phentermine/Topiramate (Qsymia)

Qsymia is FDA-approved for chronic weight management and is generally less expensive than Saxenda. The CONQUER trial (N=2,487) showed a mean weight loss of 9.8% at 56 weeks with the top dose (15 mg/92 mg) versus 1.2% with placebo. The trial was published in The Lancet. [10] Qsymia is contraindicated in pregnancy and requires enrollment in a Risk Evaluation and Mitigation Strategy (REMS) program.

Bupropion/Naltrexone (Contrave)

Contrave produces modest weight loss (approximately 5% mean body weight reduction versus placebo at 56 weeks in the COR-I trial, N=1,742) and may be available at a lower tier on some BCBSAZ formularies. COR-I was published in The Lancet. [11] It is not appropriate for patients with seizure disorders, active eating disorders, or those taking opioids.

Tirzepatide (Zepbound)

Zepbound (tirzepatide 2.5 to 15 mg weekly) received FDA approval for weight management in November 2023. The SURMOUNT-1 trial (N=2,539) demonstrated a mean weight loss of 20.9% at 72 weeks with the 15 mg dose versus 3.1% with placebo (P<0.001). Published in the New England Journal of Medicine. [12] Formulary placement varies widely, but Zepbound may be preferred on plans that have updated their GLP-1 tier structure for 2024 or 2025.

Manufacturer Savings Programs and Assistance Options

Even with insurance denial, cost-reduction tools exist.

Novo Nordisk Patient Assistance Program

Novo Nordisk operates a patient assistance program for uninsured or underinsured patients. Eligibility is income-based, generally requiring household income at or below 400% of the federal poverty level. Applications are submitted at NovoCare or by calling 1-866-310-7549.

Saxenda Savings Card

For commercially insured patients whose plan covers Saxenda but with high cost-sharing, Novo Nordisk's savings card may reduce out-of-pocket costs to as low as $25 per month for eligible patients. The card is not valid for Medicare, Medicaid, or other government-funded plans. FDA guidance on drug manufacturer coupons clarifies the legal boundaries of these programs. [13]

340B Pharmacy Programs

Federally Qualified Health Centers (FQHCs) and other safety-net providers can dispense medications at 340B discounted prices, which may reduce Saxenda's cost substantially for qualifying patients. The Health Resources and Services Administration explains 340B eligibility criteria. [14]

Dosing Schedule for Saxenda

The FDA-approved titration schedule minimizes gastrointestinal side effects. Prescribers follow this ramp-up:

| Week | Daily Dose | |------|-----------| | 1 | 0.6 mg | | 2 | 1.2 mg | | 3 | 1.8 mg | | 4 | 2.4 mg | | 5 onward | 3.0 mg (maintenance) |

The FDA label specifies that patients who do not lose at least 4% of baseline body weight by week 16 should discontinue Saxenda because it is unlikely to be effective. [1] This criterion is also used by insurers to determine whether to continue coverage after the initial approval period.

Saxenda is injected subcutaneously into the abdomen, thigh, or upper arm once daily at any time, with or without food. The prescribing information at FDA.gov details injection technique and storage requirements (refrigerate at 36 to 46°F until first use, then store at room temperature up to 77°F for up to 30 days). [1]

Side Effects That Affect PA Documentation and Tolerability

Documenting side effects from previous weight-loss medications strengthens a medical necessity argument when requesting a step-therapy exception for Saxenda.

The most common Saxenda side effects are gastrointestinal. In the SCALE trials, nausea occurred in 39.3% of liraglutide-treated patients versus 14.5% with placebo. Vomiting affected 15.7% versus 3.9%, and diarrhea 20.9% versus 9.9%. [6] Most GI effects are dose-dependent and attenuate over four to eight weeks of use. The NIH MedlinePlus drug information page for liraglutide provides plain-language side-effect summaries for patient education. [7]

Serious but rare adverse events include acute pancreatitis, gallbladder disease, increased heart rate, and suicidal ideation. The FDA added a warning about thyroid C-cell tumors based on rodent carcinogenicity studies. Clinically, no human cases have been causally linked, but the label requires disclosure. [1]

What BCBSAZ Members Should Do Right Now

The most direct path forward is a three-step sequence.

First, call the member services number on the back of your BCBSAZ card and ask the representative to read you the current formulary tier and PA criteria for Saxenda (NDC prefix 00169) for your specific plan ID. Request that the criteria be sent to you in writing.

Second, schedule an in-person or telehealth visit with your prescriber specifically to discuss Saxenda coverage. Bring your most recent weight history, any prior diet-program records, and a list of current comorbidities. A documented office visit that references obesity using ICD-10-CM E66.01 (morbid obesity due to excess calories) is stronger than a phone request.

Third, if your prescriber determines Saxenda is the appropriate agent and submits a PA that is denied, initiate the first-level internal appeal within 60 days. Attach the SCALE Obesity and Prediabetes NEJM publication [6] and the AACE obesity guideline reference [4] to every appeal submission.

Members whose plan year runs January to December should confirm formulary placement in October or November, before the new benefit year takes effect, because tier placement can change annually. A drug covered on Tier 3 in 2024 may shift to Tier 4 or be excluded entirely in 2025.